Negative Pressure Incisional Wound Therapy for High-risk Ventral Hernia Repair (N-PITH)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04455724 |
Recruitment Status :
Recruiting
First Posted : July 2, 2020
Last Update Posted : March 17, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ventral Hernia | Device: Negative pressure incisional wound therapy Device: Standard sterile dressing | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 110 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Investigator, Outcomes Assessor) |
Masking Description: | Given the physical differences in the negative pressure wound therapy systems compared to standard sterile dressings, patient participants and care providers will not be able to be blinded. Ultrasound evaluators and statisticians, however, will be. |
Primary Purpose: | Treatment |
Official Title: | Negative Pressure Incisional Wound Therapy for High-risk Ventral Hernia Repair: a Randomized Controlled Trial |
Actual Study Start Date : | December 14, 2020 |
Estimated Primary Completion Date : | July 31, 2024 |
Estimated Study Completion Date : | July 31, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Negative Pressure Incisional Wound Therapy
A PREVENA™ PEEL & PLACE™ system kit will be applied to the surgical wound and assembled in the operating room following closure by primary intent. The system will be set for a negative pressure of -125mmHg. The dressing will be left in place for 7 days post-operation, during which the patient may be discharged from hospital. The dressing will only be removed or changed if the treating physician has suspicion of one of the complications included in the primary composite outcome or is planning re-intervention on the surgical site.
|
Device: Negative pressure incisional wound therapy
A vacuum-style dressing system that is sealed in place over a surgical wound, applying constant negative pressure to the healing tissues. |
Active Comparator: Standard sterile dressing
A sterile island dressing will be applied to the surgical wound in the operating room following closure by primary intent, which will be removed on post-operative day 2 and left open to air unless there is ongoing discharge.
|
Device: Standard sterile dressing
A standard, sterile island dressing |
- Surgical Site Complications [ Time Frame: First 3 months post-operatively ]Composite of incidence of surgical site infection, hematoma formation, seroma formation, wound dehiscence, hernia recurrence, and fistula formation.
- Quality of life after surgery: survey [ Time Frame: 3 months post-operatively ]Quality of life as measured using the Hernia-Related Quality of Life Survey (HerQLes). Scoring is out of 100, with higher scores indicating better quality of life.
- Cost-effectiveness [ Time Frame: 3 months post-operatively ]Cost in dollars per quality-adjusted life year, measured using hospital length of stay, cost of complications, and cost of intervention
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- patients undergoing surgical repair of ventral or incisional hernias greater than 3 cm in largest diameter
-
have one or more of the following risk factors for post-operative surgical site complications:
- Body Mass Index (BMI) greater than or equal to 30
- diagnosis of diabetes mellitus (either type I or II)
- previous history of hernia recurrence
- active smoker
- presence of colostomy or ileostomy
- age greater than 64
- chronic obstructive pulmonary disease
- chronic kidney disease
- clinically immunocompromised.
Exclusion Criteria:
- the abdomen is left open post-operatively, or
- if the patient has a sensitivity to silver.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04455724
Contact: Nathan E How, MD | 613-539-1337 | nathan.how@medportal.ca | |
Contact: Christopher Blewett, MD | 289 606 1333 | blewettc@gmail.com |
Canada, Ontario | |
Niagara Health St. Catharines Site | Recruiting |
St. Catharines, Ontario, Canada, L2R 2A8 | |
Contact: Nathan How, MD |
Principal Investigator: | Christopher E Blewett, MD | McMaster University |
Responsible Party: | McMaster University |
ClinicalTrials.gov Identifier: | NCT04455724 |
Other Study ID Numbers: |
8183 |
First Posted: | July 2, 2020 Key Record Dates |
Last Update Posted: | March 17, 2023 |
Last Verified: | March 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | Yes |
Hernia Hernia, Ventral Pathological Conditions, Anatomical Hernia, Abdominal |